Kristina Jankovic, Medical Oncology Resident at University Clinical Center Nis, shared a post on X:
“They say not to take trials personally…
But when it’s called KRISTINE you pay extra attention….
Neoadjuvant therapy in HER2+ early Breast Cancer:
- TCH+P leads to higher pCR.
- T-DM1+P leads to better tolerability.”
